Do you want to know factors influencing Orphan PnR in Spain?

//Do you want to know factors influencing Orphan PnR in Spain?

Do you want to know factors influencing Orphan PnR in Spain?

Omakase has presented at ISPOR 2022 in Vienna the following POSTER: “Do you want to know factors influencing Orphan PnR in Spain?”

The analysis has shown a clinical and regulatory variables that could be relevant for Pricing and Reimbursement (P&R) decisions for Orphan Drugs (OD) in Spain. the analysis has shown that ODs might be more likely to be reimbursed in Spain if they have a positive TPR conclusion (80% were reimbursed), if indicated for an ultra-rare disease (63% were reimbursed), if their clinical programme is based on survival-related outcomes (57% were reimbursed), if they are approved without conditional approval (55% were reimbursed) and if directed to an oncology indication (51% were reimbursed). Economic variables could not be assessed in this study because of lack of transparency in public sources.

2024-04-02T10:30:41+00:00November 24th, 2022|Abstracts/posters|